MEK5 Recombinant Monoclonal Antibody

$Western blot analysis of Hela cell lysate. Using MEK5 (bsm-63027R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n$

Western blot analysis of Hela cell lysate. Using MEK5 (bsm-63027R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n

Applications

WB
IF(ICC)

Reactivity

Human

Overview
Catalog #	bsm-63027r-100ul
Product Name	MEK5 Recombinant Monoclonal Antibody
Applications	WB, IF(ICC)
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human MEK5
Clonality	Monoclonal
Clone #	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Storage Condition	Shipped at 4°. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	5607
Swiss Prot	Q13163
Synonyms	MAP2K5; HsT17454; MAPKK 5; MEK 5; MAPKK5; MEK5; MKK5; MAP kinase kinase 5; PRKMK5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5.
Background	Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. As part of the MAPK/ERK signaling pathway, acts as a negative regulator of apoptosis in cardiomyocytes via promotion of STUB1/CHIP-mediated ubiquitination and degradation of ICER-type isoforms of CREM.
Application Dilution
WB	1:300-5000
IF(ICC)	1:50-200